Genetic mutations in NOTCH1 are found in approximately 11% of CLL patients (8) and cause increased canonical and non-canonical NF-κB activity (27), which correlate with CLL cell survival and poor response to chemotherapy agents (28–30). Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.